Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
Main Authors: | Zhidong Jiang, Bo Feng, Yumin Zhang, Tianqing Nie, Hong Liu, Jia Li, Haixia Su, Leike Zhang, Yi Zang, Yu Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-05-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-023-01482-9 |
Similar Items
-
Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
by: Zhidong Jiang, et al.
Published: (2023-10-01) -
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
by: Lijing Zhang, et al.
Published: (2024-04-01) -
A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir
by: Yumin Zhang, et al.
Published: (2023-09-01) -
Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
by: Yi Kuang, et al.
Published: (2023-04-01) -
3CLpro inhibitors: DEL-based molecular generation
by: Feng Xiong, et al.
Published: (2022-12-01)